| Literature DB >> 25965915 |
Charles Guenancia1, Christine Binquet2, Gabriel Laurent3, Sandrine Vinault4, Rémi Bruyère5, Sébastien Prin5, Arnaud Pavon6, Pierre-Emmanuel Charles5, Jean-Pierre Quenot7.
Abstract
PURPOSE: We investigated incidence, risk factors for new-onset atrial fibrillation (NAF), and prognostic impact during septic shock in medical Intensive Care Unit (ICU) patients.Entities:
Mesh:
Year: 2015 PMID: 25965915 PMCID: PMC4428753 DOI: 10.1371/journal.pone.0127168
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Probability of new-onset AF during the 7 first days of septic shock (Kaplan-Meier curve).
Baseline Characteristics According To The Onset Of Atrial Fibrillation.
| n (%), median [interquartile range], mean ± SD | New-onset AF | Sinus rhythm | P |
|---|---|---|---|
| n = 29 (44%) | n = 37 (56%) | ||
|
| |||
| Age, years | 71.0 ±13.5 | 60.5 +/- 13.5 | <0.001 |
| Female sex | 11 (37.9) | 13 (35.1) | 0.81 |
| Systemic hypertension | 16 (55.2) | 18 (48.7) | 0.60 |
| Hypercholesterolemia | 11 (37.9) | 7 (18.9) | 0.08 |
| Active Smoking | 4 (13.8) | 12 (32.4) | 0.08 |
| Diabetes mellitus | 7 (24.1) | 7 (18.9) | 0.61 |
| BMI, m2/kg | 26.3 [24.6–29.3] | 24.6 [21.1–30.1] | 0.17 |
|
| |||
| B-blocker | 9 (31.0) | 8 (21.6) | 0.39 |
| Calcium antagonist | 9 (31.0) | 5 (13.5) | 0.08 |
| ACE inhibitor | 11 (37.9) | 8 (21.6) | 0.15 |
| Diuretic | 6 (20.7) | 7 (18.9) | 0.86 |
| Antiplatelet therapy | 7 (24.1) | 4 (10.8) | 0.19 |
| VKA | 4 (13.8) | 1 (2.7) | 0.16 |
|
| |||
| CAD | 6 (20.7) | 4 (10.8) | 0.31 |
| Valvular disease | 1 (3.5) | 2 (5.4) | 1 |
| Other cardiopathy | 10 (34.5) | 8 (21.6) | 0.24 |
| Previous hyperthyroidism | 2 (6.9) | 1 (2.7) | 0.58 |
| Previous hypothyroidism | 5 (17.2) | 2 (5.4) | 0.23 |
| Previous pulmonary embolism | 1 (3.5) | 1 (2.7) | 1 |
| Immunodepression | 14 (48.3) | 12 (32.4) | 0.19 |
| Previous health status (Knaus) | 0.65 | ||
| A | 3 (10.3) | 6 (16.2) | |
| B | 18 (62.1) | 19 (51.4) | |
| C | 8 (27.6) | 10 (27.0) | |
| D | 0 | 2 (5.4) |
ACE indicates angiotensin conversion enzyme; AF: atrial fibrillation; BMI: body mass index; CAD: Coronary Artery Disease; SD: standard deviation; SR: Sinus Rhythm; VKA: Vitamin K Antagonists.
Echocardiographic Characteristics According To The Onset Of Atrial Fibrillation.
| n (%), median [interquartile range], mean ± SD | New-onset AF | Maintained SR | P |
|---|---|---|---|
| n = 29 (43.9) | n = 37 (56.1) | ||
| LVEF <45% | 7 (25) | 1 (3) | <0.01 |
| LVEF | 51 +/- 13 | 59 +/- 6 | <0.01 |
|
| |||
| Mild | 8 (27.6) | 9 (25.7) | 0.87 |
| Moderate or severe | 2 (6.9) | 2 (5.7) | 1 |
| Pericardial effusion | 2 (6.9) | 2 (5.4) | 1 |
| Left atrial surface >20 cm2 | 10 (55.6) | 10 (41.7) | 0.37 |
|
| |||
| E velocity | 0.75 [0.66–0.95] | 0.80 [0.59–1.03] | 0.95 |
| E/e’ | 9.9 [6.0–10.7] | 8.0 [6.3–10.0] | 0.46 |
| Diastolic dysfunction | 13 (54.2) | 10(41.7) | 0.39 |
| TAPSE | 22.4 [16.0–23.6] | 22.6 [19.0–25.0] | 0.27 |
| S Wave | 16.6 [13.0–18.3] | 15.2 [12.3–17.3] | 0.69 |
| Right ventricular dysfunction | 7 (36.8) | 3 (11.5) | 0.07 |
| Elevated Right Atrial Pressure (IVC>2cm) | 6 (35.3) | 5 (20.0) | 0.30 |
AF indicates atrial fibrillation; IVC: inferior vena cava; LVEF: left ventricular ejection fraction; TAPSE: tricuspid annular plane systolic excursion.
Clinical and Biological Characteristics According To The Onset Of Atrial Fibrillation.
| n (%), median [interquartile range], mean ± SD | New-onset AF | Maintained SR | P |
|---|---|---|---|
| n = 29 (43.9) | n = 37 (56.1) | ||
|
| |||
| SAPS II score | 56 [45–71] | 50 [39–57] | 0.13 |
| SOFA score | 10.9 +/- 2.9 | 10.9 +/- 3.2] | 0.89 |
|
| |||
| Metabolic acidosis | 26 (89.7) | 32 (86.5) | 1 |
| Oliguria/ Renal failure | 18 (62.1) | 23 (62.2) | 0.99 |
| Hepatic dysfunction | 4 (13.8) | 10 (27.0) | 0.19 |
| Surgical Emergency | 2 (6.9) | 1 (2.7) | 0.58 |
| Nosocomial infection | 6 (20.7) | 10 (27.0) | 0.55 |
|
| |||
| Pulmonary | 19 (65.5) | 26 (70.3) | 0.68 |
| Urinary | 7 (24.1) | 6 (16.2) | 0.42 |
| Gastrointestinal | 5 (17.2) | 6 (16.2) | 1 |
|
| |||
| Anemia <10g/dl | 23 (79.3) | 30 (81.1) | 0.86 |
| Hyperthyroidism | 6 (20.7) | 8 (26.7) | 0.59 |
| Hypercalcemia | 12 (41.4) | 10 (27.0) | 0.22 |
| Hyperkaliemia | 7 (24.1) | 6 (16.2) | 0.42 |
| Hypokaliemia | 22 (75.9) | 32 (86.5) | 0.27 |
| Lactate peak, mmol/l | 6.5 +/- 6.2 | 6.3 +/- 7.0 | 0.72 |
| Troponin peak>100 ULN | 9 (32.1) | 2 (5.6) | <0.01 |
| NT pro BNP peak, pg/ml | 9433 [4988–27745] | 2536 [798–9490] | 0.01 |
| Procalcitonin peak, μg/L | 30.4 [3.5–153.0] | 13.7 [2.6–32.1] | 0.09 |
| Delta total protein level (max-min)/max, g/l | 0.24 [0.17–0.29] | 0.20 [0.15–0.32] | 0.82 |
AF indicates atrial fibrillation; NT pro BNP: n terminal pro brain natriuretic peptide; SAPS II: simplified acute physiological score; SOFA: sequential organ failure assessment
Rhythmic Characteristics According To The Onset Of Atrial Fibrillation.
| n (%), median [interquartile range], mean ± SD | New-onset AF | Maintained SR | P |
|---|---|---|---|
| n = 29 (43.9) | n = 37 (56.1) | ||
|
| |||
| P wave duration >100ms | 6 (25.0) | 3 (9.1) | 0.15 |
| QRS duration (ms) | 86.5 [80.0–100.0] | 80.0 [80.0–90.0] | 0.04 |
| QRS duration >120 ms | 5 (19.2) | 1 (3.0) | 0.08 |
| QTc duration (ms) | 431.5 [414–467] | 412.0 [382–454] | 0.07 |
|
| |||
| PAC day 1 | 110 [73–131] | 87 [66–110] | 0.11 |
| PVC day 1 | 60 [36–93] | 48 [32–76] | 0.56 |
| NSVT day 1 | 2.5 +/- 7.0 | 0 +/- 0 | <0.01 |
| Time delay between admission and first AF record (days) | 1.7 +/- 1.5 | ||
| Total duration of AF during Holter ECG monitoring (hours) | 18.6 +/- 35.4 | ||
| Number of AF episodes during Holter ECG monitoring | 1.8 +/- 1.4 | ||
| Silent AF | 10 (34.5) |
AF indicates atrial fibrillation; ECG: electrocardiogram; QTc: corrected QT; NSVT: Nonsustained Supra ventricular tachycardia; PAC: premature atrial contraction; PVC: premature ventricular contraction.
In-ICU Management According To The Onset Of Atrial Fibrillation.
| n (%), median [interquartile range], mean ± SD | New-onset AF | Maintained SR | P |
|---|---|---|---|
| n = 29 (43.9) | n = 37 (56.1) | ||
|
| |||
| Norepinephrine duration (days) | 4 [3–7] | 3 [2–5] | 0.11 |
| Mechanical Ventilation | 22 (75.9) | 32 (86.5) | 0.27 |
| Mechanical Ventilation duration (days) | 10 [7–16] | 8 [5–16] | 0.50 |
|
| 16 (55.2) | 14 (37.8) | 0.16 |
| CVVHD duration (days) | 5 [3–6] | 6 [5–9] | 0.55 |
| Intermittent hemodialysis (number) | 4 [2–6] | 3 [2–3] | 0.78 |
| Hydrocortisone | 19 (65.5) | 26 (70.3) | 0.68 |
| Inotropic catecholamine | 4 (13.8) | 2 (5.4) | 0.39 |
| Anticoagulation | 22 (75.9) | 10 (27.0) | <0.01 |
| Amiodarone | 19 (65.5) | 3 (8.1) | <0.01 |
|
| |||
| Crystalloids (l) | 2.9 +/- 1.5 | 3.0 +/- 1.9 | 0.98 |
| Colloids (l) | 0.3 +/- 0.5 | 0.3 +/- 0.5 | 0.52 |
|
| |||
| ICU stay duration (days) | 10 [4–17] | 7 [4–14] | 0.76 |
| ICU death | 7 (24.1) | 7 (18.9) | 0.61 |
| In-hospital stay duration (days) | 22 [14–41] | 26 [8–40] | 1 |
| In-hospital death | 9 (31.0) | 9 (24.3) | 0.54 |
| 90 days death | 12 (41.4) | 16 (43.2) | 0.88 |
AF indicates atrial fibrillation; CVVHD: continuous veno-venous hemodialysis; ICU: intensive care unit.